Benefits
Cellular Energy Support
NADH is the reduced electron-carrier coenzyme that feeds Complex I of the mitochondrial electron transport chain, the upstream input to ATP synthesis. Supplemental stabilized NADH may help maintain cellular energy production, particularly in tissues with high metabolic demand such as muscle, brain, and heart.
Mental Clarity and Focus
By supporting mitochondrial ATP production in neurons and serving as a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, NADH may help maintain mental clarity, alertness, and cognitive readiness during periods of fatigue or sleep deprivation.
Fatigue Symptom Support
Small placebo-controlled work in chronic fatigue populations suggests stabilized oral NADH may modestly reduce subjective fatigue symptoms. Effects are not curative and individual response varies; the supplement is best viewed as one part of a broader energy-support strategy.
Jet Lag and Travel Fatigue
NADH has been studied as a counter-fatigue agent during simulated jet lag and overnight travel scenarios. By transiently supporting cellular energetics it may help maintain reaction time and cognitive performance after time-zone shifts or disrupted sleep.
Dopaminergic Support
NADH supplies reducing equivalents needed by tyrosine hydroxylase to convert tyrosine into L-DOPA, the precursor to dopamine. This biochemical role has driven research into NADH for dopamine-dependent functions, including motor smoothness and motivational drive.
Mechanism of action
Electron Transport Chain Input
NADH donates electrons to NADH dehydrogenase (Complex I) of the inner mitochondrial membrane, initiating oxidative phosphorylation. This proton-pumping cascade drives ATP synthase, the body's primary source of usable cellular energy.
Tyrosine Hydroxylase Cofactor
NADH provides reducing equivalents required for tetrahydrobiopterin regeneration, the obligate cofactor of tyrosine hydroxylase. This enzyme catalyzes the rate-limiting step in catecholamine biosynthesis, producing L-DOPA en route to dopamine and norepinephrine.
Sirtuin Substrate Pool
NADH (along with oxidized NAD+) sits within the cellular NAD pool that fuels sirtuin deacetylases, PARP DNA-repair enzymes, and CD38. Maintaining adequate NAD pool size supports longevity-linked enzymatic activity in aging cells.
Stabilized Oral Bioavailability
Microencapsulated and pH-protected formulations resist gastric acid hydrolysis, allowing intact NADH to reach intestinal absorption sites. This compensates for the molecule's notorious oral instability and degradation in unprotected powder form.
Clinical trials
Randomized, double-blind, placebo-controlled crossover trial of stabilized oral NADH (10 mg/day) vs placebo for 4 weeks each in 26 adults meeting CDC criteria for chronic fatigue syndrome. Outcomes: symptom severity scores, quality of life measures.
26 adults with CDC-diagnosed chronic fatigue syndrome. 4-week crossover periods.
31% of patients receiving NADH reported favorable response (>10% improvement on global symptom scale) compared to 8% on placebo. Treatment was well-tolerated with no significant adverse events. The trial is small and exploratory but represents the foundational placebo-controlled human evidence for stabilized oral NADH in fatigue states.
Large uncontrolled open-label trial of 885 Parkinson's disease patients, roughly half receiving NADH by intravenous infusion and half by oral capsules. Outcomes: author-rated disability improvement and comparison of oral vs parenteral response. No placebo control.
Adults with idiopathic Parkinson's disease.
By author rating in this uncontrolled open-label trial, about 80% of patients were reported to show some benefit (roughly 19% a 30-50% improvement in disability and 59% a 10-30% improvement), and oral NADH produced improvement comparable to the parenteral form. Because there was no placebo control and the ratings were unblinded, these results are highly susceptible to bias; they have not been independently reproduced in modern blinded trials, and the cited paper did not report L-DOPA biosynthesis marker data. This remains the basis for NADH's marketed Parkinson's-adjacent positioning.